20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
Clinical, non-clinical, technological, and industrial data will be collected throughout the project. Confidential and sensitive data related to the AI tool and participants in the clinical trials will be kept restricted and will not be published. Non-sensitive publishable data will possibly be shared through publications and made accessible to the research community for verification, re-use, and cross-validation scientific purposes.
The collected data will be primarily used for the purpose of further development of the AI-based tool, IP protection, but also for results dissemination and communication to interested stakeholders, including the scientific community, key opinion leaders, patients the and broad public. Data from clinical studies will be public and accessible from the University Hospital of Rome Tor Vergata (IT). We will value our IP through direct commercial exploitation of HELIXAFE tests and further analysis of the customer’s data through the optimized AI algorithm.
